Global Amyotrophic Lateral Sclerosis Market Research Report - Forecast to 2023

Date: March 1, 2019
Pages: 115
Price:
US$ 4,450.00
License [?]:
Publisher: Market Research Future
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G81DA63B69CEN
Leaflet:

Download PDF Leaflet

Global Amyotrophic Lateral Sclerosis Market Research Report - Forecast to 2023
Amyotrophic Lateral Sclerosis Market Research Report: By Type (Familial ALS), by Treatment (Medication, Physical Therapy, Speech Therapy), by Diagnosis (Laboratory Tests, Imaging Tests), End-User (Hospitals, Specialty Centers) – Global forecast till 2023

Market analysis

Amyotrophic lateral sclerosis (ALS) belongs to a group of neurological disease. Otherwise called motor neuron diseases, they influence the engine elements of voluntary muscles in the body. Factors, for example, an expansion in the occurrence rate of ALS, grow in the awareness about the ailment among patients, and ascend in the geriatric populace is relied upon to help the development of the amyotrophic lateral sclerosis market. Other factors including the tendency towards the stationary way of life are driving the market development and expanding the danger of getting attacked by ALS. Furthermore, the expanding geriatric populace substantiates market development, making interest in symptomatic and focused on treatment alternatives. However, the staggering expense of the treatment of ALS may impede market development over the figure time frame. The market is growing at 7.89 % CAGR and is expected to reach the valuation of USD 841.6 million by the year 2023.

Market segmentation

The Global amyotrophic lateral sclerosis market has been classified on the basis of its treatment, type, end-user, and regional demand. Based on its type, the market is classified into familial ALS and sporadic. On the basis of its treatment, the market has been segmented into physical therapy, speech therapy, medication, respiratory therapy, and others. By its end-user, the ALS market has been segmented into research & academic institutes, specialty centers, hospitals, and others.

Regional analysis

Geographically, the Global amyotrophic lateral sclerosis market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major players

Mylan N.V. (U.S.), Covis Pharma (Switzerland), Ionis Pharmaceutical (U.S.), ITF Pharma (U.S.), Ascend Pharmaceuticals LLC (U.S.), Apotex Inc. (Canada), Sun Pharmaceutical (India), Mitsubishi Tanabe Pharma America (U.S.), Biogen (U.S.), Sanofi (France), among others are some of the major players in the Global amyotrophic lateral sclerosis market.
1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 Definition
2.2 Scope of the Study
2.3 List of Assumptions
2.4 Market Structure

3 RESEARCH METHODOLOGY

3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model

4 MARKET DYNAMICS

4.1 Overview
4.2 Drivers
  4.2.1 Growing Incidence of Amyotrophic Lateral Sclerosis (ALS)
  4.2.2 Rising Geriatric Population
  4.2.3 Growing Awareness about Amyotrophic Lateral Sclerosis
4.3 Restraints
  4.3.1 High Cost of ALS Treatment
4.4 Opportunities
  4.4.1 Increasing Strategic Collaborations of Major Companies and Research Institutes for the Development of ALS Treatment

5 MARKET FACTOR ANALYSIS

5.1 Porter’s Five Forces Model
  5.1.1 Bargaining Power of Suppliers
  5.1.2 Bargaining Power of Buyers
  5.1.3 Threat of New Entrants
  5.1.4 Threat of Substitutes
  5.1.5 Intense Rivalry
5.2 Value Chain Analysis
  5.2.1 Raw Material Sourcing
  5.2.2 Manufacturing
  5.2.3 Distribution & Sales
  5.2.4 Post-Sales Monitoring
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

6 GLOBAL AMYOTROPHIC LATERAL SCLEROSIS MARKET, BY TYPE

6.1 Overview
6.2 Sporadic ALS
6.3 Familial ALS

7 GLOBAL AMYOTROPHIC LATERAL SCLEROSIS MARKET, BY TREATMENT

7.1 Overview
7.2 Medication
7.3 Physical Therapy
7.4 Respiratory Therapy
7.5 Speech Therapy
7.6 Others

8 GLOBAL AMYOTROPHIC LATERAL SCLEROSIS MARKET, BY END USER

8.1 Overview
8.2 Hospitals
8.3 Specialty Centers
8.4 Research and Academic Institutes
8.5 Others

9 GLOBAL AMYOTROPHIC LATERAL SCLEROSIS MARKET, BY REGION

9.1 Overview
9.2 Americas
  9.2.1 North America
    9.2.1.1 US
    9.2.1.2 Canada
  9.2.2 Latin America
9.3 Europe
  9.3.1 Western Europe
    9.3.1.1 Germany
    9.3.1.2 France
    9.3.1.3 UK
    9.3.1.4 Italy
    9.3.1.5 Spain
    9.3.1.6 Rest of Western Europe
  9.3.2 Eastern Europe
9.4 Asia-Pacific
  9.4.1 Japan
  9.4.2 Australia
  9.4.3 China
  9.4.4 India
  9.4.5 South Korea
  9.4.6 Rest of Asia-Pacific
9.5 Middle East & Africa
  9.5.1 Middle East
  9.5.2 Africa

10 COMPANY LANDSCAPE

10.1 Overview
10.2 Company Ranking

11 COMPANY PROFILE

11.1 Ascend Laboratories LLC
  11.1.1 Company Overview
  11.1.2 Financial Overview
  11.1.3 Products/Services Offered
  11.1.4 SWOT Analysis
  11.1.5 Key Developments
  11.1.6 Key Strategy
11.2 Apotex Inc.
  11.2.1 Company Overview
  11.2.2 Financial Overview
  11.2.3 Products/Services Offered
  11.2.4 SWOT Analysis
  11.2.5 Key Developments
  11.2.6 Key strategy
11.3 Biogen
  11.3.1 Company Overview
  11.3.2 Financial Overview
  11.3.3 Products/Services Offered
  11.3.4 SWOT Analysis
  11.3.5 Key Developments
  11.3.6 Key strategy
11.4 Covis Pharma
  11.4.1 Company Overview
  11.4.2 Financial Overview
  11.4.3 Products/Services Offered
  11.4.4 SWOT Analysis
  11.4.5 Key Developments
  11.4.6 Key Strategy
11.5 Ionis Pharmaceuticals
  11.5.1 Company Overview
  11.5.2 Financial Overview
  11.5.3 Products/Services Offered
  11.5.4 SWOT Analysis
  11.5.5 Key Developments
  11.5.6 Key Strategy
11.6 ITF Pharma
  11.6.1 Company Overview
  11.6.2 Financial Overview
  11.6.3 Products/Services Offered
  11.6.4 Key Developments
  11.6.5 SWOT Analysis
  11.6.6 Key Strategy
11.7 Mitsubishi Tanabe Pharma America
  11.7.1 Company Overview
  11.7.2 Financial Overview
  11.7.3 Products/Services Offered
  11.7.4 SWOT Analysis
  11.7.5 Key Developments
  11.7.6 Key strategy
11.8 Mylan N.V.
  11.8.1 Company Overview
  11.8.2 Financial Overview
  11.8.3 Products/Services Offered
  11.8.4 SWOT Analysis
  11.8.5 Key Developments
  11.8.6 Key Strategy
11.9 Sanofi
  11.9.1 Company Overview
  11.9.2 Financial Overview
  11.9.3 Products/Services Offered
  11.9.4 SWOT Analysis
  11.9.5 Key Developments
  11.9.6 Key Strategy
11.1 Sun Pharmaceutical Industries Ltd
  11.10.1 Company Overview
  11.10.2 Financial Overview
  11.10.3 Products/Services Offered
  11.10.4 SWOT Analysis
  11.10.5 Key Development
  11.10.6 Key Strategy

12 APPENDIX

12.1 Discussion Blue Print

LIST OF TABLES:

TABLE 1 MARKET SYNOPSIS
TABLE 2 LIST OF ASSUMPTIONS
TABLE 3 GLOBAL ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 4 GLOBAL ALS MARKET FOR SPORADIC ALS, BY REGION, 2015–2023 (USD MILLION)
TABLE 5 GLOBAL ALS MARKET FOR FAMILIAL ALS, BY REGION, 2015–2023 (USD MILLION)
TABLE 6 GLOBAL ALS MARKET FOR TREATMENT, 2015–2023 (USD MILLION)
TABLE 7 GLOBAL ALS MARKET FOR MEDICATION, BY REGION, 2015–2023 (USD MILLION)
TABLE 8 GLOBAL ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 9 GLOBAL ALS MARKET FOR PHYSICAL THERAPY, BY REGION, 2015–2023 (USD MILLION)
TABLE 10 GLOBAL ALS MARKET FOR RESPIRATORY THERAPY, BY REGION, 2015–2023 (USD MILLION)
TABLE 11 GLOBAL ALS MARKET FOR SPEECH THERAPY, BY REGION, 2015–2023 (USD MILLION)
TABLE 12 GLOBAL ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 13 GLOBAL ALS MARKET FOR HOSPITALS, BY REGION, 2015–2023 (USD MILLION)
TABLE 14 GLOBAL ALS MARKET FOR SPECIALTY CENTERS, BY REGION, 2015–2023 (USD MILLION)
TABLE 15 GLOBAL ALS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2015–2023 (USD MILLION)
TABLE 16 GLOBAL ALS MARKET, BY REGION, 2015–2023 (USD MILLION)
TABLE 17 AMERICAS: ALS MARKET, BY REGION, 2015–2023 (USD MILLION)
TABLE 18 AMERICAS: ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 19 AMERICAS: ALS MARKET, BY TREATMENT, 2015–2023 (USD MILLION)
TABLE 20 AMERICAS: ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 21 AMERICAS: ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 22 NORTH AMERICA: ALS MARKET, BY COUNTRY, 2015–2023 (USD MILLION)
TABLE 23 NORTH AMERICA: ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 24 NORTH AMERICA: ALS MARKET, BY TREATMENT, 2015–2023 (USD MILLION)
TABLE 25 NORTH AMERICA: ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 26 NORTH AMERICA: ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 27 US: ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 28 US: ALS MARKET, BY TREATMENT, 2015–2023 (USD MILLION)
TABLE 29 US: ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 30 US: ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 31 CANADA: ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 32 CANADA: ALS MARKET, BY TREATMENT, 2015–2023 (USD MILLION)
TABLE 33 CANADA: ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 34 CANADA: ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 35 LATIN AMERICA: ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 36 LATIN AMERICA: ALS MARKET, BY TREATMENT, 2015–2023 (USD MILLION)
TABLE 37 LATIN AMERICA: ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 38 LATIN AMERICA: ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 39 EUROPE: ALS MARKET, BY REGION, 2015–2023 (USD MILLION)
TABLE 40 EUROPE: ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 41 EUROPE: ALS MARKET, BY TREATMENT, 2015–2023 (USD MILLION)
TABLE 42 EUROPE: ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 43 EUROPE: ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 44 WESTERN EUROPE: ALS MARKET, BY COUNTRY, 2015–2023 (USD MILLION)
TABLE 45 WESTERN EUROPE: ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 46 WESTERN EUROPE: ALS MARKET, BY TREATMENT, 2015–2023 (USD MILLION)
TABLE 47 WESTERN EUROPE: ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 48 WESTERN EUROPE: ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 49 GERMANY: ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 50 GERMANY: ALS MARKET, BY TREATMENT, 2015–2023 (USD MILLION)
TABLE 51 GERMANY: ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 52 GERMANY: ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 53 FRANCE: ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 54 FRANCE: ALS MARKET, BY TREATMENT, 2015–2023 (USD MILLION)
TABLE 55 FRANCE: ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 56 FRANCE: ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 57 UK: ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 58 UK: ALS MARKET, BY TREATMENT, 2015–2023 (USD MILLION)
TABLE 59 UK: ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 60 UK: ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 61 ITALY: ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 62 ITALY: ALS MARKET, BY TREATMENT, 2015–2023 (USD MILLION)
TABLE 63 ITALY: ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 64 ITALY: ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 65 SPAIN: ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 66 SPAIN: ALS MARKET, BY TREATMENT, 2015–2023 (USD MILLION)
TABLE 67 SPAIN: ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 68 SPAIN: ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 69 REST OF WESTERN EUROPE: ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 70 REST OF WESTERN EUROPE: ALS MARKET, BY TREATMENT, 2015–2023 (USD MILLION)
TABLE 71 REST OF WESTERN EUROPE: ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 72 REST OF WESTERN EUROPE: ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 73 EASTERN EUROPE: ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 74 EASTERN EUROPE: ALS MARKET, BY TREATMENT, 2015–2023 (USD MILLION)
TABLE 75 EASTERN EUROPE: ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 76 EASTERN EUROPE: ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 77 ASIA-PACIFIC: ALS MARKET, BY COUNTRY, 2015–2023 (USD MILLION)
TABLE 78 ASIA-PACIFIC: ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 79 ASIA-PACIFIC: ALS MARKET, BY TREATMENT, 2015–2023 (USD MILLION)
TABLE 80 ASIA-PACIFIC: ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 81 ASIA-PACIFIC: ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 82 JAPAN: ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 83 JAPAN: ALS MARKET, BY TREATMENT, 2015–2023 (USD MILLION)
TABLE 84 JAPAN: ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 85 JAPAN: ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 86 AUSTRALIA: ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 87 AUSTRALIA: ALS MARKET, BY TREATMENT, 2015–2023 (USD MILLION)
TABLE 88 AUSTRALIA: ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 89 AUSTRALIA: ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 90 CHINA: ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 91 CHINA: ALS MARKET, BY TREATMENT, 2015–2023 (USD MILLION)
TABLE 92 CHINA: ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 93 CHINA: ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 94 INDIA: ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 95 INDIA: ALS MARKET, BY TREATMENT, 2015–2023 (USD MILLION)
TABLE 96 INDIA: ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 97 INDIA: ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 98 SOUTH KOREA: ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 99 SOUTH KOREA: ALS MARKET, BY TREATMENT, 2015–2023 (USD MILLION)
TABLE 100 SOUTH KOREA: ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 101 SOUTH KOREA: ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 102 REST OF ASIA-PACIFIC: ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 103 REST OF ASIA-PACIFIC: ALS MARKET, BY TREATMENT, 2015–2023 (USD MILLION)
TABLE 104 REST OF ASIA-PACIFIC: ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 105 REST OF ASIA-PACIFIC: ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 106 AFRICA: ALSMIDDLE EAST & AFRICA: ALS MARKET, BY REGION, 2015–2023 (USD MILLION)
TABLE 107 AFRICA: ALSMIDDLE EAST & AFRICA: ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 108 AFRICA: ALSMIDDLE EAST & AFRICA: ALS MARKET, BY TREATMENT, 2015–2023 (USD MILLION)
TABLE 109 AFRICA: ALSMIDDLE EAST & AFRICA: ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 110 AFRICA: ALSMIDDLE EAST & AFRICA: ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 111 MIDDLE EAST: ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 112 MIDDLE EAST: ALS MARKET, BY TREATMENT, 2015–2023 (USD MILLION)
TABLE 113 MIDDLE EAST: ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 114 MIDDLE EAST: ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 115 AFRICA: ALS MARKET, BY TYPE, 2015–2023 (USD MILLION)
TABLE 116 AFRICA: ALS MARKET, BY TREATMENT, 2015–2023 (USD MILLION)
TABLE 117 AFRICA: ALS MARKET FOR MEDICATION, BY DRUG, 2015–2023 (USD MILLION)
TABLE 118 AFRICA: ALS MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 119 GLOBAL AMYOTROPHIC LATERAL SCLEROSIS MARKET: MAJOR PLAYER RANKING, 2017

LIST OF FIGURES:

FIGURE 1 GLOBAL AMYOTROPHIC LATERAL SCLEROSIS MARKET: MARKET STRUCTURE
FIGURE 2 RESEARCH PROCESS OF MRFR
FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACHES
FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL AMYOTROPHIC LATERAL SCLEROSIS MARKET
FIGURE 5 PORTER’S FIVE FORCES ANALYSIS: GLOBAL AMYOTROPHIC LATERAL SCLEROSIS MARKET
FIGURE 6 VALUE CHAIN: GLOBAL AMYOTROPHIC LATERAL SCLEROSIS MARKET
FIGURE 7 GLOBAL ALS MARKET, BY TYPE, 2017 AND 2023 (USD MILLION)
FIGURE 8 GLOBAL ALS MARKET, BY TREATMENT, 2017 AND 2023 (USD MILLION)
FIGURE 9 GLOBAL ALS MARKET, BY END USER, 2017 AND 2023 (USD MILLION)
FIGURE 10 GLOBAL ALS MARKET, BY REGION, 2017 AND 2023 (USD MILLION)
FIGURE 11 AMERICAS: ALS MARKET, BY REGION, 2017 (%)
FIGURE 12 NORTH AMERICA: ALS MARKET, BY COUNTRY, 2017 (%)
FIGURE 13 EUROPE: ALS MARKET, BY REGION, 2017 (%)
FIGURE 14 WESTERN EUROPE: ALS MARKET, BY COUNTRY, 2017 (%)
FIGURE 15 ASIA-PACIFIC: ALS MARKET, BY COUNTRY, 2017 (%)
FIGURE 16 AFRICA: ALSMIDDLE EAST & AFRICA: ALS MARKET, BY REGION, 2017 (%)
Skip to top


Ask Your Question

Global Amyotrophic Lateral Sclerosis Market Research Report - Forecast to 2023
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: